Aurealis pre-clinical stage asset AUP-55 consists of genetically engineered lactic acid bacteria for the treatment of ovarian cancer, peritoneal carcinomatosis and bladder cancer. In ovarian cancer models in mice, treatment with AUP-55 resulted in 91.3 % survival and lower tumour load compared to 0 % survival and massively increased tumour load in untreated subjects.

Aurealis Therapeutics have provided the following sources to better demonstrate the capabilities of AUP-55:

• Product Presentation
• Relevant Publication (Journal of Clinical Oncology)